CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 2 enrolled
Drug / intervention
Dexrazoxanedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01596088
NCT01596088Phase 2Completed
CompareCT.gov

A Multicenter, Open Label, Single-arm Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

Kissei Pharmaceutical Co., Ltd.·interventional·Posted May 10, 2012·Updated Apr 7, 2015

In Brief

A Phase 2 clinical trial evaluating Dexrazoxane for Extravasations of Anthracycline Anti-cancer Agents. Completed, enrolled 2 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of KDX-0811(Dexrazoxane) in the treatment of accidental extravasation of anthracycline anti-cancer agents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtravasations of Anthracycline Anti-cancer Agents
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 10, 2012
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Posted 14.1 years ago

Interventions

Dexrazoxanedrug